Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Paradigm Biopharmaceuticals Ltd

PAR.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: BUY

Last Close

$0.14

▲ +14.29%

Market Cap $87.81M · Vol 8.24M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$87.81M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

-78.24%

YoY

RSI (14)

56.25

Momentum

Beta

1.61

vs Market

52W High

$0.34

53.29% below

52W Low

$0.10

51.26% above

Volume

8.24M

Avg 1.80M

P/B

5.61

Price-to-book

ROE

-72.18%

Return on equity

Free Float

89.97%

Public shares

Shariah Compliance8 STANDARDS

✗ Paradigm Biopharmaceuticals Ltd (PAR.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PAR.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+14.29%

+21.21%

+17.65%

-25.93%

YTD

-41.18%

-35.48%

-67.65%

-89.27%

Financials & Valuation

TTM · Annual

Total Revenue	$4.68M
Net Income	$-12,351,128.00
Revenue Growth (YoY)	-34.50%
Gross Margin	99.71%
Operating Margin	-228.51%
Net Profit Margin	-264.18%
ROE	-72.18%
ROA · ROIC	-70.91% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	16.72
P/B	5.61
P/FCF	N/A
EPS Growth	-78.24%
Outstanding Shares	599.19M

Technical Indicators

50-Day SMA	$0.12
200-Day SMA	$0.17
RSI (14)	56.25
Beta	1.61
52-Week High	$0.34
52-Week Low	$0.10

Volume Today	8.24M
Avg Daily Volume (30D)	1.80M
Relative Volume	4.58x
Volatility (10D)	77.66
Volatility (30D)	75.08
Free Float	89.97%

Analyst Consensus

BUY

Current Price $0.14

Mean Target $0.29

52W Low$0.10 52W High$0.34

Current

Target

$0.10 $0.34

Current Analyst target

+106.24% upside potential · 1 analysts

Identifiers

ExchangeASX

FIGIBBG009QNWX94

ISINAU000000PAR5

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 26, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -0.74% RVMD Revolution Medicines Inc +1.01% ONC BeOne Medicines AG -0.66% 068270.KS Celltrion Inc +0.88% ABVX Abivax SA +1.04%

Company Profile

Paradigm Biopharmaceuticals Limited is a late-stage drug development company engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). PPS is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans. It develops PPS under the brand name Zilosul. Other indications under investigation for PPS include the treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses; treating alphavirus-induced arthralgia; chronic heart failure; acute respiratory distress syndrome; and allergic respiratory conditions. It is also advancing early formulation development for Pentacoxib, an oral combination of PPS and a COX-2 inhibitor targeting patients with earlier-stage OA.